- Home
- ESRT vs CSTL Comparison
ESRT vs CSTL Comparison
Compare ESRT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESRT | CSTL |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 940.8M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ESRT | CSTL |
|---|---|---|
| Price | $6.42 | $32.34 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.80 | ★ $46.67 |
| AVG Volume (30 Days) | ★ 1.4M | 409.4K |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $766,184,000.00 | $343,530,000.00 |
| Revenue This Year | $1.95 | $2.88 |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | $33.14 | ★ N/A |
| Revenue Growth | 1.02 | ★ 10.15 |
| 52 Week Low | $6.09 | $14.59 |
| 52 Week High | $9.66 | $44.28 |
Technical Indicators
Market Signals| Indicator | ESRT | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 27.34 |
| Support Level | $6.60 | $31.64 |
| Resistance Level | $6.79 | $33.10 |
| Average True Range (ATR) | 0.21 | 1.93 |
| MACD | 0.01 | -0.99 |
| Stochastic Oscillator | 13.68 | 9.15 |
Price Performance
Historical ComparisonAbout ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.